BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Academic Article
Publication Date:
2022
Citation:
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update / M. Reig, A. Forner, J. Rimola, J. Ferrer-Fàbrega, M. Burrel, Á. Garcia-Criado, R.K. Kelley, P.R. Galle, V. Mazzaferro, R. Salem, B. Sangro, A.G. Singal, A. Vogel, J. Fuster, C. Ayuso, J. Bruix. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 76:3(2022), pp. 681-693. [10.1016/j.jhep.2021.11.018]
abstract:
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.
IRIS type:
01 - Articolo su periodico
Keywords:
AFP; ALBI score; BCLC; HCC; TARE; ablation; liver transplantation TACE; surgery; survival; systemic treatment; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Prognosis
List of contributors:
M. Reig, A. Forner, J. Rimola, J. Ferrer-Fàbrega, M. Burrel, Á. Garcia-Criado, R.K. Kelley, P.R. Galle, V. Mazzaferro, R. Salem, B. Sangro, A.G. Singal, A. Vogel, J. Fuster, C. Ayuso, J. Bruix
Link to information sheet: